76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Dr Reddy's Laboratories Ltd-ADR
Open
SectorHealthcare
14.43 0.14
Overview
Share price change
24h
Min
14.23
Max
14.45
Income | 1.5B 14B |
|---|---|
Sales | 3.4B 84B |
P/E Sector Avg | 18.329 56.602 |
EPS | 19.11 |
Dividend yield | 0.71 |
Profit margin | 16.795 |
EBITDA | 2.4B 24B |
Dividend yield Sector Avg | 0.71% 2.45% |
|---|
Market Cap | 9.3B 12B |
|---|---|
Previous open | 14.29 |
Previous close | 14.43 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Dr Reddy's Laboratories Ltd-ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Dr Reddy's Laboratories Ltd-ADR Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Dr Reddy's Laboratories Ltd-ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
